Type 1 Diabetes

Christopher Lucci, MD, reviews the current diagnostic tests for hypercortisolism, which include the Dexamethasone Suppression Test, DHEA level tests, and ACTH assessments.

The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!

Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

In this episode, Alan Lotvin, MD, of Sequel Med Tech, joins hosts for a deep dive into the twiist automated insulin delivery system, which received clearance for people with T1D in March 2024.

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

In this episode, hosts discuss top news and updates in automated insulin delivery from ATTD 2024, with a focus on new data from the T1D Exchange and a read-out from the CRISTAL study.

Jake Leach, COO of Dexcom, joins the podcast to discuss the historic clearance of the Stelo sensor and other updates in CGM from the company.

The FDA has cleared Sequel's twiist, a novel automated insulin delivery system, expanding patient choice for individuals with type 1 diabetes.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

The FDA has greenlit Dexcom's Stelo Glucose Biosensor System, marking a historic first as the first continuous glucose monitors to be available over-the-counter.

Hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.

Hosts break down their favorite sessions at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes.

Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range and other advanced CGM metrics with diabetic retinopathy and the implications for use in predicting other microvascular outcomes.

Viral Shah, MD, of Indiana University, joins Diabetes Dialogue to discuss a recent proof-of-concept study examining use of tirzepatide in type 1 diabetes.

A new study found balance and falling were linked to an increased risk of all-cause mortality, as well as cause-specific mortality from cardiovascular disease and diabetes.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

In this episode, hosts discuss recent news and updates in diabetes technology from Abbott, Dexcom, and Medtronic in the first half of January 2024.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

A new study identified T1D as a risk factor associated with nearly all subtypes of CHD, whereas overweight was associated only with certain defect types.

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management.